AUSTIN, Texas--(BUSINESS WIRE)--July 26, 2006--Asuragen, Inc., an oncology molecular diagnostic company and molecular biology service provider, announces that it has entered into a semi-exclusive licensing agreement with Rockefeller University for the diagnostic rights to its proprietary microRNA sequences. Through this agreement, Asuragen will have access to microRNAs identified by a group led by Rockefeller University researcher, Thomas Tuschl, Ph.D., a distinguished thought leader in the discovery and application of siRNAs and microRNAs. The microRNAs have been found to have expression profiles and functions involved with human diseases like diabetes and cancer.
